Germany-based Eckert & Ziegler is expanding its activities on gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.
The companies notified the Japanese Pharmaceuticals and Medical Devices Agency that Eckert & Ziegler’s proprietary Ge-68/Ga-68 generator GalliaPharm will be the single source for Ga-68 in a trial. The first GalliaPharm was delivered for the study in January and will be followed by several further generators until mid-2025.
The trial (NCT06240741) will investigate the diagnostic performance of Ga-68 DOTATATE PET/CT imaging in patients with neuroendocrine neoplasms.
